Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seamless phase II/III randomized double-blind active-controlled study of hepunofovir fumarate tablets for chronic hepatitis B
CTR20252906Phase 3Active
- Sponsor
- Qifang Pharmaceutical
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of hepunofovir fumarate in Chronic Hepatitis B (CHB), sponsored by Qifang Pharmaceutical. Started Jul 2025; status: active.
02
Drugs
hepunofovir fumarate
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on CTR20252906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252906.